8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Sheryl Cartwright
8.8
- - Biostatistical Design
- - 4 weeks May - June 2023
- - Research Institution
Reviewed:
Excellent biostatistical support, clear and actionable insights.
The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.
Israel Grady
5.8
- - Biostatistical Design
- - 6 weeks February - March 2024
- - Research Institution
Reviewed:
Biostatistical analysis lacked depth, missed key insights.
The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.
Bernice Gutmann
6.2
- - Clinical Protocol Design
- - 10 weeks January - March 2024
- - Pharmaceutical Company
Reviewed:
Inconsistent quality of deliverables, frequent revisions needed.
The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.
Maryann Strosin I
8.9
- - Stability Studies
- - 18 months January 2023 - June 2024
- - Pharmaceutical Company
Reviewed:
Accurate and reliable stability studies, clear reporting.
The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.
Cory Gleichner
9.2
- - Data Visualization
- - 3 weeks December 2023
- - Pharmaceutical Company
Reviewed:
Highly effective data visualization, easy to interpret and impactful.
The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.
Julius Padberg
9.3
- - Market Access Strategy
- - 6 weeks January - February 2024
- - Pharmaceutical Company
Reviewed:
Strategic market access analysis, insightful recommendations.
The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.
